BRAF and metastatic neoplasm: The identification of certain gene mutations (adenomatous polyposis coli (APC), Kirsten RAS proto-oncogene GTPase (KRAS), B-Raf proto-oncogene serine/threonine kinase (BRAF), etc.), as well as the characterization of microsatellite instability, has been included in disease profiling and therapeutic planning mainly for patients with metastatic disease [3,4].